BRPI0516233A - complexo compreendendo a mequitazina, uma ciclodextrina, e um agente de interação, processo de preparação do mesmo, e, composição farmacêutica destinada a ser administrada por via oral - Google Patents

complexo compreendendo a mequitazina, uma ciclodextrina, e um agente de interação, processo de preparação do mesmo, e, composição farmacêutica destinada a ser administrada por via oral

Info

Publication number
BRPI0516233A
BRPI0516233A BRPI0516233-5A BRPI0516233A BRPI0516233A BR PI0516233 A BRPI0516233 A BR PI0516233A BR PI0516233 A BRPI0516233 A BR PI0516233A BR PI0516233 A BRPI0516233 A BR PI0516233A
Authority
BR
Brazil
Prior art keywords
mequitazine
complex
cyclodextrin
pharmaceutical composition
preparing
Prior art date
Application number
BRPI0516233-5A
Other languages
English (en)
Inventor
Bernard Freiss
Hubert Lochard
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BRPI0516233A publication Critical patent/BRPI0516233A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

COMPLEXO COMPREENDENDO A MEQUITAZINA, UMA CICLODEXTRINA, E UM AGENTE DE INTERACãO, PROCESSO DE PREPARAçãO DO MESMO, E, COMPOSIçãO FARMACêUTICA DESTINADA A SER ADMINISTRADA POR VIA ORAL. A presente invenção refere-se a um complexo compreendendo a mequitazina, uma ciclodextrina e um agente de interação caracterizado em que a taxa de solubilização na água da mequitazina complexada, medida para uma misturas a 2 g/1 de mequitazina em água a 35 °C, após 15 minutos de agitação, é superior a 50% a pH 9. Ela refere-se igualmente a um processo de preparação deste complexo e uma composição farmacêutica compreendendo o mesmo.
BRPI0516233-5A 2004-10-21 2005-10-19 complexo compreendendo a mequitazina, uma ciclodextrina, e um agente de interação, processo de preparação do mesmo, e, composição farmacêutica destinada a ser administrada por via oral BRPI0516233A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0411202A FR2876910B1 (fr) 2004-10-21 2004-10-21 Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
PCT/EP2005/055388 WO2006042857A2 (fr) 2004-10-21 2005-10-19 Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction

Publications (1)

Publication Number Publication Date
BRPI0516233A true BRPI0516233A (pt) 2008-08-26

Family

ID=34949969

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516233-5A BRPI0516233A (pt) 2004-10-21 2005-10-19 complexo compreendendo a mequitazina, uma ciclodextrina, e um agente de interação, processo de preparação do mesmo, e, composição farmacêutica destinada a ser administrada por via oral

Country Status (18)

Country Link
US (1) US7749982B2 (pt)
EP (1) EP1802348A2 (pt)
JP (1) JP5157447B2 (pt)
KR (1) KR101273840B1 (pt)
CN (1) CN101043908B (pt)
AR (1) AR051593A1 (pt)
AU (1) AU2005296875B2 (pt)
BR (1) BRPI0516233A (pt)
CA (1) CA2583783C (pt)
FR (1) FR2876910B1 (pt)
IL (1) IL182412A (pt)
MX (1) MX2007004787A (pt)
NO (1) NO20072433L (pt)
NZ (1) NZ555238A (pt)
RU (1) RU2389491C2 (pt)
TW (1) TWI372759B (pt)
WO (1) WO2006042857A2 (pt)
ZA (1) ZA200703080B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2914187B1 (fr) * 2007-03-28 2011-01-21 Pf Medicament Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique.
JP7029886B2 (ja) * 2017-04-28 2022-03-04 ロート製薬株式会社 医薬組成物及びその製造方法
KR20220085094A (ko) 2020-12-14 2022-06-22 메디케어제약 주식회사 알레르기성 결막염을 동반한 만성 비염을 치료하는 약제학적 복합제제

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1250534A (pt) 1969-03-03 1971-10-20
FR2522660A1 (fr) * 1982-03-05 1983-09-09 Pharmuka Lab Isomere levogyre de la mequitazine, son procede de preparation et medicaments le contenant
IT1196033B (it) 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
US4975426A (en) * 1987-06-08 1990-12-04 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
JP2735122B2 (ja) * 1988-06-13 1998-04-02 旭化成工業株式会社 メキタジンの液状シロップ製剤
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
KR920006911B1 (ko) * 1989-06-14 1992-08-22 신풍제약 주식회사 안정한 피록시캄 주사액 조성물 및 그의 제조방법
RU2097025C1 (ru) * 1990-11-06 1997-11-27 Ниппон Синяку Компани, Лимитед Лиофилизированный препарат жировой эмульсии и способ его получения
TW262497B (en) 1994-06-29 1995-11-11 Toshiba Co Ltd Washing machine
FR2742053B1 (fr) * 1995-12-06 1998-03-06 Chauvin Lab Sa Compositions pharmaceutiques a base de mequitazine
WO1998002186A1 (en) * 1996-07-11 1998-01-22 Farmarc Nederland B.V. Inclusion complex containing indole selective serotonin agonist
JPH10167954A (ja) * 1996-12-05 1998-06-23 Takada Seiyaku Kk メキタジン製剤
GB9800936D0 (en) 1997-05-10 1998-03-11 Univ Nottingham Biofunctional polymers
DE69911159T2 (de) * 1999-01-06 2004-06-24 Técnimede-Sociedade Técnico-Medicinal, S.A. Cyclodextrin Einschlusskomplexe mit Aminosäuresalzen von Benzimidazolderivaten, deren Herstellung, sowie diese enthaltende pharmazeutische Zusammensetzungen
FR2788436A1 (fr) * 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
FR2815540B1 (fr) * 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
WO2002089851A1 (fr) * 2001-03-06 2002-11-14 Separex (Societe Anonyme) Procede de fabrication de complexes hote-client
FR2830761B1 (fr) 2001-10-12 2003-12-12 Pf Medicament Procede de preparation d'un compose d'interaction d'un derive anilide avec un support poreux par fluide supercritique
FR2830760B1 (fr) 2001-10-12 2004-06-04 Pf Medicament Procede de preparation d'un compose d'interaction de substances actives avec un support poreux par fluide supercritique
FR2854079B1 (fr) 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
DK2260871T3 (da) 2004-04-01 2013-08-26 Pf Medicament Inklusionskomplekser omfattende piroxicam, en cyklodextrin og arginin

Also Published As

Publication number Publication date
WO2006042857A3 (fr) 2006-07-27
US20070293454A1 (en) 2007-12-20
JP2008517035A (ja) 2008-05-22
RU2007118640A (ru) 2008-11-27
CN101043908B (zh) 2011-11-16
FR2876910A1 (fr) 2006-04-28
IL182412A (en) 2015-02-26
KR20070084223A (ko) 2007-08-24
RU2389491C2 (ru) 2010-05-20
US7749982B2 (en) 2010-07-06
EP1802348A2 (fr) 2007-07-04
JP5157447B2 (ja) 2013-03-06
IL182412A0 (en) 2007-07-24
AU2005296875A1 (en) 2006-04-27
AR051593A1 (es) 2007-01-24
AU2005296875B2 (en) 2011-03-31
CN101043908A (zh) 2007-09-26
CA2583783C (fr) 2013-05-21
NZ555238A (en) 2010-04-30
CA2583783A1 (fr) 2006-04-27
FR2876910B1 (fr) 2007-04-13
KR101273840B1 (ko) 2013-06-11
ZA200703080B (en) 2008-05-28
WO2006042857A2 (fr) 2006-04-27
TW200621770A (en) 2006-07-01
TWI372759B (en) 2012-09-21
MX2007004787A (es) 2007-05-15
NO20072433L (no) 2007-05-11

Similar Documents

Publication Publication Date Title
BR0313723A (pt) Derivados de benzotiazol tendo atividade de agonista beta-2-adrenorreceptor
BRPI0407897A (pt) derivados de cianopiridina úteis no tratamento de cáncer e outros distúrbios
BRPI0710485B1 (pt) composições líquidas úteis no tratamento de doenças respiratórias
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
TW200733968A (en) Stabilized lanthanum carbonate compositions
BRPI0500704A (pt) composições de tratamento pessoal reidratáveis
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
AR076153A1 (es) Forma de dosificacion intra-oral de multiples porciones con propiedades organolepticas. formulaciones
BRPI0407485A (pt) utilização de anticorpos anti-receptores de factor crescimento i semelhantes aos anti-insulina
BRPI0418148A (pt) composto, prodroga de um composto, modulador da função do receptor gpr40, agente farmacêutico, uso de um composto e métodos de modificação de uma função do receptor gpr40 em um mamìfero, de profilaxia ou tratamento de diabetes em um mamìfero e de produção de um composto
CL2008001839A1 (es) Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
BRPI0906181A2 (pt) "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
TW200700093A (en) Pharmaceutical composition for the treatment of cancer
BRPI0517500A (pt) compostos, uso de uma composição, composição farmacêutica, composição cosmética, uso não-terapêutico de uma composição cosmética e processo cosmético para melhorar a aparência da pele
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
EA200900451A1 (ru) Способ получения композиции эстрадиола с медленным высвобождением ( варианты ), микросферы эстрадиола и холестерина и способ для одновременной контрацепции и гормонозамещения
NO20025999D0 (no) Klart, vandig anestetisk preparat
BRPI0507544A (pt) combinação de agonistas de benzotiazol-2-ona beta-2 adrenoreceptores e corticosteróides para o tratamento de doenças respiratórias
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
BR112016007010A2 (pt) composição de higiene oral anidro e método de fabricação de uma mistura de tratamento
BRPI0513278A (pt) uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton
BRPI0916282B8 (pt) uso de um agonista do receptor-pgi2 no tratamento de insuficiência renal crônica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2433 DE 22-08-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: B82Y 5/00 (2011.01), A61K 47/69 (2017.01)